Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease

Takahito Moriyama, Yuki Tsuruta, Chiari Kojima, Mitsuyo Itabashi, Hidekazu Sugiura, Takashi Takei, Tetsuya Ogawa, Keiko Uchida, Ken Tsuchiya, Kosaku Nitta

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background Blockade of the renin-angiotensin- aldosterone system is a therapeutic mainstay in patients with chronic kidney disease (CKD). However, the renoprotective effect of the novel direct renin inhibitor aliskiren is unknown. Materials and methods We performed a prospective study in 10 CKD patients. All 10 patients with persistent proteinuria (urinary protein-to-creatinin ratio 0.3-3.5 g/g), despite good blood pressure control (<130/80 mmHg) with olmesartan, were started on 150 mg/day aliskiren. Clinical parameters were examined before and after 4, 8, 12, and 16 weeks of treatment. Results Urinary protein-to-creatinine ratio significantly decreased by about 40% at 16 weeks from baseline (P = 0.0002), although estimated glomerular filtration rate and blood pressure did not change throughout the study period. Plasma renin activity also decreased significantly from baseline (P = 0.019), although plasma aldosterone concentration did not change. Conclusions Aliskiren combined with olmesartan reduces proteinuria in CKD patients.

Original languageEnglish (US)
Pages (from-to)841-845
Number of pages5
JournalInternational Urology and Nephrology
Volume44
Issue number3
DOIs
StatePublished - Jun 2012

Fingerprint

Chronic Renal Insufficiency
Proteinuria
Renin
Proteins
Blood Pressure
Renin-Angiotensin System
Aldosterone
Glomerular Filtration Rate
Creatinine
Prospective Studies
aliskiren
olmesartan
Therapeutics

Keywords

  • Aliskiren
  • Chronic kidney disease
  • Olmesartan
  • Proteinuria

ASJC Scopus subject areas

  • Nephrology
  • Urology

Cite this

Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease. / Moriyama, Takahito; Tsuruta, Yuki; Kojima, Chiari; Itabashi, Mitsuyo; Sugiura, Hidekazu; Takei, Takashi; Ogawa, Tetsuya; Uchida, Keiko; Tsuchiya, Ken; Nitta, Kosaku.

In: International Urology and Nephrology, Vol. 44, No. 3, 06.2012, p. 841-845.

Research output: Contribution to journalArticle

Moriyama, T, Tsuruta, Y, Kojima, C, Itabashi, M, Sugiura, H, Takei, T, Ogawa, T, Uchida, K, Tsuchiya, K & Nitta, K 2012, 'Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease', International Urology and Nephrology, vol. 44, no. 3, pp. 841-845. https://doi.org/10.1007/s11255-011-9991-0
Moriyama, Takahito ; Tsuruta, Yuki ; Kojima, Chiari ; Itabashi, Mitsuyo ; Sugiura, Hidekazu ; Takei, Takashi ; Ogawa, Tetsuya ; Uchida, Keiko ; Tsuchiya, Ken ; Nitta, Kosaku. / Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease. In: International Urology and Nephrology. 2012 ; Vol. 44, No. 3. pp. 841-845.
@article{10fb901bcaf147f1bc65f5efcc4d6436,
title = "Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease",
abstract = "Background Blockade of the renin-angiotensin- aldosterone system is a therapeutic mainstay in patients with chronic kidney disease (CKD). However, the renoprotective effect of the novel direct renin inhibitor aliskiren is unknown. Materials and methods We performed a prospective study in 10 CKD patients. All 10 patients with persistent proteinuria (urinary protein-to-creatinin ratio 0.3-3.5 g/g), despite good blood pressure control (<130/80 mmHg) with olmesartan, were started on 150 mg/day aliskiren. Clinical parameters were examined before and after 4, 8, 12, and 16 weeks of treatment. Results Urinary protein-to-creatinine ratio significantly decreased by about 40{\%} at 16 weeks from baseline (P = 0.0002), although estimated glomerular filtration rate and blood pressure did not change throughout the study period. Plasma renin activity also decreased significantly from baseline (P = 0.019), although plasma aldosterone concentration did not change. Conclusions Aliskiren combined with olmesartan reduces proteinuria in CKD patients.",
keywords = "Aliskiren, Chronic kidney disease, Olmesartan, Proteinuria",
author = "Takahito Moriyama and Yuki Tsuruta and Chiari Kojima and Mitsuyo Itabashi and Hidekazu Sugiura and Takashi Takei and Tetsuya Ogawa and Keiko Uchida and Ken Tsuchiya and Kosaku Nitta",
year = "2012",
month = "6",
doi = "10.1007/s11255-011-9991-0",
language = "English (US)",
volume = "44",
pages = "841--845",
journal = "International Urology and Nephrology",
issn = "0301-1623",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease

AU - Moriyama, Takahito

AU - Tsuruta, Yuki

AU - Kojima, Chiari

AU - Itabashi, Mitsuyo

AU - Sugiura, Hidekazu

AU - Takei, Takashi

AU - Ogawa, Tetsuya

AU - Uchida, Keiko

AU - Tsuchiya, Ken

AU - Nitta, Kosaku

PY - 2012/6

Y1 - 2012/6

N2 - Background Blockade of the renin-angiotensin- aldosterone system is a therapeutic mainstay in patients with chronic kidney disease (CKD). However, the renoprotective effect of the novel direct renin inhibitor aliskiren is unknown. Materials and methods We performed a prospective study in 10 CKD patients. All 10 patients with persistent proteinuria (urinary protein-to-creatinin ratio 0.3-3.5 g/g), despite good blood pressure control (<130/80 mmHg) with olmesartan, were started on 150 mg/day aliskiren. Clinical parameters were examined before and after 4, 8, 12, and 16 weeks of treatment. Results Urinary protein-to-creatinine ratio significantly decreased by about 40% at 16 weeks from baseline (P = 0.0002), although estimated glomerular filtration rate and blood pressure did not change throughout the study period. Plasma renin activity also decreased significantly from baseline (P = 0.019), although plasma aldosterone concentration did not change. Conclusions Aliskiren combined with olmesartan reduces proteinuria in CKD patients.

AB - Background Blockade of the renin-angiotensin- aldosterone system is a therapeutic mainstay in patients with chronic kidney disease (CKD). However, the renoprotective effect of the novel direct renin inhibitor aliskiren is unknown. Materials and methods We performed a prospective study in 10 CKD patients. All 10 patients with persistent proteinuria (urinary protein-to-creatinin ratio 0.3-3.5 g/g), despite good blood pressure control (<130/80 mmHg) with olmesartan, were started on 150 mg/day aliskiren. Clinical parameters were examined before and after 4, 8, 12, and 16 weeks of treatment. Results Urinary protein-to-creatinine ratio significantly decreased by about 40% at 16 weeks from baseline (P = 0.0002), although estimated glomerular filtration rate and blood pressure did not change throughout the study period. Plasma renin activity also decreased significantly from baseline (P = 0.019), although plasma aldosterone concentration did not change. Conclusions Aliskiren combined with olmesartan reduces proteinuria in CKD patients.

KW - Aliskiren

KW - Chronic kidney disease

KW - Olmesartan

KW - Proteinuria

UR - http://www.scopus.com/inward/record.url?scp=84864285441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864285441&partnerID=8YFLogxK

U2 - 10.1007/s11255-011-9991-0

DO - 10.1007/s11255-011-9991-0

M3 - Article

C2 - 21626132

AN - SCOPUS:84864285441

VL - 44

SP - 841

EP - 845

JO - International Urology and Nephrology

JF - International Urology and Nephrology

SN - 0301-1623

IS - 3

ER -